Brief: United Laboratories International Updates On Imipenem & Cilastatin Sodium For Injection
17/01/2024 14:47
Jan 17 (Reuters) - United Laboratories International
Holdings Ltd 3933.HK :
* IMIPENEM & CILASTATIN SODIUM FOR INJECTION WITH APPROVAL
OF
CHINA NMPA PASSED CONSISTENCY EVALUATION
* IMIPENEM & CILASTATIN SODIUM FOR INJECTION PASSED
CONSISTENCY
EVALUATION OF QUALITY & EFFICACY FOR GENERIC DRUG
Source text for Eikon: ID:n11041538-1
Further company coverage: 3933.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million